MX2022011729A - Dosificación qw de compuestos peptídicos agonistas del receptor de gip y sus usos. - Google Patents

Dosificación qw de compuestos peptídicos agonistas del receptor de gip y sus usos.

Info

Publication number
MX2022011729A
MX2022011729A MX2022011729A MX2022011729A MX2022011729A MX 2022011729 A MX2022011729 A MX 2022011729A MX 2022011729 A MX2022011729 A MX 2022011729A MX 2022011729 A MX2022011729 A MX 2022011729A MX 2022011729 A MX2022011729 A MX 2022011729A
Authority
MX
Mexico
Prior art keywords
receptor agonist
agonist peptide
peptide compounds
gif
gip receptor
Prior art date
Application number
MX2022011729A
Other languages
English (en)
Inventor
Antoine Charles Olivier Henninot
Derek Cecil Cole
Nicholas Scorah
Original Assignee
Takeda Pharmaceuticals Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Takeda Pharmaceuticals Co filed Critical Takeda Pharmaceuticals Co
Publication of MX2022011729A publication Critical patent/MX2022011729A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/26—Glucagons
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575—Hormones
    • C07K14/605—Glucagons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/08—Drugs for disorders of the alimentary tract or the digestive system for nausea, cinetosis or vertigo; Antiemetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Endocrinology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Diabetes (AREA)
  • Toxicology (AREA)
  • Immunology (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Epidemiology (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Emergency Medicine (AREA)
  • Child & Adolescent Psychology (AREA)
  • Hospice & Palliative Care (AREA)
  • Otolaryngology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Medicinal Preparation (AREA)

Abstract

La presente divulgación proporciona compuestos peptídicos agonistas del receptor de GIP adecuados para dosificación una vez a la semana (QW), en los que dichos compuestos peptídicos tienen una acción activadora sobre los receptores de GIP, y el uso del péptido agonista del receptor de GIP como medicamento para el tratamiento y/o la prevención de la emesis o un síntoma o una afección asociados con la emesis. Específicamente, se proporciona un péptido agonista del receptor de GIP que contiene una secuencia representada por cualquiera de las fórmulas (I)-(V) o una sal de este y un medicamento que lo comprende.
MX2022011729A 2020-03-25 2021-03-25 Dosificación qw de compuestos peptídicos agonistas del receptor de gip y sus usos. MX2022011729A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US202062994721P 2020-03-25 2020-03-25
PCT/JP2021/014422 WO2021193983A2 (en) 2020-03-25 2021-03-25 Qw dosing of gip receptor agonist peptide compounds and uses thereof

Publications (1)

Publication Number Publication Date
MX2022011729A true MX2022011729A (es) 2022-10-13

Family

ID=75674909

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2022011729A MX2022011729A (es) 2020-03-25 2021-03-25 Dosificación qw de compuestos peptídicos agonistas del receptor de gip y sus usos.

Country Status (17)

Country Link
US (1) US20230143604A1 (es)
EP (1) EP4126920A2 (es)
JP (1) JP2023524603A (es)
KR (1) KR20220157409A (es)
CN (1) CN115916812A (es)
AR (1) AR121649A1 (es)
AU (1) AU2021243671A1 (es)
BR (1) BR112022019110A2 (es)
CA (1) CA3172241A1 (es)
CL (1) CL2022002597A1 (es)
CO (1) CO2022014960A2 (es)
EC (1) ECSP22074715A (es)
IL (1) IL296219A (es)
MX (1) MX2022011729A (es)
PE (1) PE20221727A1 (es)
TW (1) TW202202517A (es)
WO (1) WO2021193983A2 (es)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2023139106A2 (en) * 2022-01-18 2023-07-27 Novo Nordisk A/S Long-acting gipr antagonists

Family Cites Families (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1997010224A1 (en) 1995-09-13 1997-03-20 Takeda Chemical Industries, Ltd. Benzoxazepine compounds, their production and use as lipid lowering agents
US20030187023A1 (en) 2000-07-17 2003-10-02 Keiji Kubo Sulfone derivatives, process for their production and use thereof
BR0315815A (pt) 2002-11-01 2005-09-13 Takeda Pharmaceutical Agentes para prevenir ou tratar neuropatia, para promover a produção ou a secreção de um fator neurotrópico, para melhorar a dor, neuroprotetor e farmacêutico, composto, métodos para prevenir ou tratar neuropatia e para promover a produção ou a secreção de um fator neurotrópico, para melhorar a dor para proteger um nervo em um mamìfero e para produzir um composto e uso de um composto
EP2385032A1 (en) 2002-11-08 2011-11-09 Takeda Pharmaceutical Company Limited GPR40 Receptor function regulator
EP1564213A4 (en) 2002-11-22 2009-05-27 Takeda Pharmaceutical IMIDAZOLE DERIVATIVES, PROCESS FOR THE PRODUCTION AND USE THEREOF
EP1630152A4 (en) 2003-05-30 2009-09-23 Takeda Pharmaceutical CONNECTION WITH CONDENSED RING
WO2005030740A1 (ja) 2003-09-30 2005-04-07 Takeda Pharmaceutical Company Limited チアゾリン誘導体およびその用途
EP1695961A4 (en) 2003-12-17 2007-10-24 Takeda Pharmaceutical UREA DERIVATIVE, METHOD FOR THE PRODUCTION AND THEIR USE
TW200523247A (en) 2003-12-25 2005-07-16 Takeda Pharmaceutical 3-(4-benzyloxyphenyl) propanoic acid derivatives
WO2005063725A1 (ja) 2003-12-26 2005-07-14 Takeda Pharmaceutical Company Limited フェニルプロパン酸誘導体
US7786165B2 (en) 2004-03-15 2010-08-31 Takeda Pharmaceutical Company Limited Aminophenylpropanoic acid derivative
EP2253315A1 (en) 2004-03-30 2010-11-24 Takeda Pharmaceutical Company Limited Alkoxyphenylpropanoic acid derivatives
TWI396686B (zh) 2004-05-21 2013-05-21 Takeda Pharmaceutical 環狀醯胺衍生物、以及其製品和用法
US8263545B2 (en) * 2005-02-11 2012-09-11 Amylin Pharmaceuticals, Inc. GIP analog and hybrid polypeptides with selectable properties
JP5094394B2 (ja) 2005-04-20 2012-12-12 武田薬品工業株式会社 縮合複素環化合物
EP1911738A4 (en) 2005-07-29 2009-12-16 Takeda Pharmaceutical PHENOXYALKANSÄUREVERBINDUNG
JP5084503B2 (ja) 2005-07-29 2012-11-28 武田薬品工業株式会社 シクロプロパンカルボン酸化合物
MX2008001386A (es) 2005-08-10 2008-04-07 Takeda Pharmaceutical Agente terapeutico para diabetes.
JP2007063225A (ja) 2005-09-01 2007-03-15 Takeda Chem Ind Ltd イミダゾピリジン化合物
ME00535B (me) 2006-06-27 2011-10-10 Takeda Pharmaceuticals Co Fuzionisana ciklična jedinjenja
WO2008021560A2 (en) * 2006-08-17 2008-02-21 Amylin Pharmaceuticals, Inc. Dpp-iv resistant gip hybrid polypeptides with selectable properties
EP2298772A1 (en) 2006-10-18 2011-03-23 Takeda Pharmaceutical Company Limited Fused heterocyclic compounds
US8410087B2 (en) 2006-10-19 2013-04-02 Takeda Pharmaceutical Company Limited Indole compound
EP2128138A1 (en) 2007-01-29 2009-12-02 Takeda Pharmaceutical Company Limited Pyrazole compound
WO2008099794A1 (en) 2007-02-09 2008-08-21 Takeda Pharmaceutical Company Limited Fused ring compounds as partial agonists of ppar-gamma
WO2008136428A1 (ja) 2007-04-27 2008-11-13 Takeda Pharmaceutical Company Limited 含窒素５員複素環化合物
WO2008156757A1 (en) 2007-06-19 2008-12-24 Takeda Pharmaceutical Company Limited Indazole compounds for activating glucokinase
EA020091B1 (ru) * 2008-08-07 2014-08-29 Ипсен Фарма С.А.С. Аналоги глюкозозависимого инсулинотропного полипептида (gip), модифицированные по n-концу
WO2010016936A1 (en) * 2008-08-07 2010-02-11 Ipsen Pharma S.A.S. Pharmaceutical compositions of analogues of glucose-dependent insulinotropic polypeptide
JOP20180028A1 (ar) * 2017-03-31 2019-01-30 Takeda Pharmaceuticals Co مركب ببتيد

Also Published As

Publication number Publication date
BR112022019110A2 (pt) 2023-01-17
CO2022014960A2 (es) 2022-11-08
WO2021193983A8 (en) 2023-05-25
US20230143604A1 (en) 2023-05-11
AU2021243671A1 (en) 2022-10-13
WO2021193983A3 (en) 2021-11-04
AR121649A1 (es) 2022-06-22
KR20220157409A (ko) 2022-11-29
CL2022002597A1 (es) 2023-06-02
IL296219A (en) 2022-11-01
EP4126920A2 (en) 2023-02-08
PE20221727A1 (es) 2022-11-04
CA3172241A1 (en) 2021-09-30
TW202202517A (zh) 2022-01-16
JP2023524603A (ja) 2023-06-12
ECSP22074715A (es) 2022-10-31
CN115916812A (zh) 2023-04-04
WO2021193983A2 (en) 2021-09-30

Similar Documents

Publication Publication Date Title
MX2021015328A (es) Agonistas del receptor del peptido-1 similar al glucagon.
PH12019502252A1 (en) Gip receptor activating peptide
TN2019000054A1 (en) Pyrazolopyridine derivative having glp-1 receptor agonist effect
PH12016501813A1 (en) 1,3-benzodioxole derivative
MX2019012819A (es) Compuesto dinucleotido ciclico bis 2'-5'-rr-(3'f-a) (3'f-a) y usos del mismo.
CR20230330A (es) Agonistas del receptor gpcr, composiciones farmaceuticas que los comprenden y métodos para su uso
ECSP055582A (es) Derivados de benzotiazol que tienen actividad agonista de beta-2-adrenorreceptor
MX2009006304A (es) Nuevos compuestos de oxadiazol.
DE602006020871D1 (de) Lineare harnstoffmimetika-antagonisten des p2y1-rezeptors zur behandlung von thromboseleiden
MX2021005945A (es) Ureas ciclicas.
TW200800967A (en) Benzimidazole thiophene compounds
PH12020551486A1 (en) Cyclopentane-based modulators of sting (stimulator of interferon genes)
MX2020008387A (es) Usos terapeuticos de agonistas glp1r.
PH12019500328A1 (en) Aza-indazole compounds for use in tendon and/or ligament injuries
JO3442B1 (ar) مضادات ذات نوع فرعي من مستقبل سوماتوستاتين 5 (sstr5)
CL2015003286A1 (es) (ciano-dimetil-metil)-(isoxazoles y -[1, 3, 4] tiadiazoles novedosos
MX2022011729A (es) Dosificación qw de compuestos peptídicos agonistas del receptor de gip y sus usos.
MX2022011816A (es) Dosificacion qd de compuestos peptidicos agonistas del receptor de gip y sus usos.
PH12019500327A1 (en) Indazole compounds for use in tendon and/or ligament injuries
PH12021551243A1 (en) Oxyntomodulin peptide analog formulations
MX2021011007A (es) Farmaco y método para tratar o prevenir las complicaciones de la diabetes mediante el uso del mismo farmaco.
UA91988C2 (ru) Фармацевтическая композиция на основе антагонистов nk2 для применения в педиатрии
WO2019078663A3 (ko) 아연염, 시클로-히스프로 및 항당뇨 약물을 유효성분으로 함유하는 당뇨병 예방 또는 치료용 약학적 조성물
MX2021004342A (es) Uso de compuesto de carbamato para prevenir, aliviar o tratar neuropatía periférica diabética o neuropatía periférica inducida por quimioterapia.
PL431666A1 (pl) Mieszanina zawierająca olej parafinowy jako owadobójczy i roztoczobójczy składnik czynny